Antitumor activity of a combination of rAd2p53 adenoviral gene therapy and radiotherapy in XXXX .

@entity1 @entity957 @entity1066 @entity876 @entity418 @entity158 @entity221
The objective of this study was to determine if a combination of recombinant adenovirus 2 @entity876 (rAd2p53) gene therapy and radiotherapy would have significantly improved outcome from @entity418 when compared to radiotherapy (RT) alone. Forty-five @entity1 diagnosed with @entity418 ( @entity957 ) were randomly assigned to one of two study arms: treatment group: rAd2p53 gene therapy  +  RT (n  =  22); and control group: radiotherapy (n  =  23). For the treatment group, rAd2p53 was injected into multiple areas of the lesion once a week for 6  weeks avoiding deep @entity1066 points. RT was administered after 3  days of injection of rAd2p53. @entity1 in the control group only received radiotherapy. The overall response rate was significantly higher in the treatment group than in control group (P  <  0.05). Furthermore, the complete response rate was 3 times higher in the treatment group than in the control group (P  <  0.05). Transient @entity221 and @entity158 at injection site were the only side effects mentioned in the treatment group. In conclusion, this recombinant virus-RT combination is significantly more beneficial in palliation than RT alone, with minor side affects. However, its role as neoadjuvant therapy prior to surgical resection needs to be further investigated.
